American Origin Unverified
This profile is unclaimed and has not been independently reviewed.
Claim & get verified
Oncotelic Therapeutics, Inc.
$0.05
+9.26%
OTC: OTLC · 15-min delayed
$70.0KRevenue · FY2023
$249.3MNet income
OTLCOTC
About Oncotelic Therapeutics, Inc.
ONCOTELIC THERAPEUTCS INC
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Reported figures
Financial summary
- Revenue FY2023
- $70.0K
- Net income
- $249.3M
- Total assets
- $393.1M
Source: SEC EDGAR · updated Jun 7, 2026
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
Market data by Polygon.io · prices are 15-minute delayed
Auto-generated
At a glance
- Profitable — net income of $249.3M in FY2023.
- Trading 50% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Oncotelic Therapeutics, Inc..
Write a review
Newsroom
News about Oncotelic Therapeutics, Inc.
Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus
SAPU Bioscience 重点介绍一篇经同行-评审的论文，揭示 TGFB2 与较年轻胰腺癌患者生存期之间的关联
SAPU Bioscience 重點報導經同業-評審的出版刊物，指出 TGFB2 與年輕胰臟癌患者的存活期息息相關
SAPU Bioscience Highlights Peer‑Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients
Oncotelic Therapeutics Implements PDAOAI Platform
ONCOTELIC TO PRESENT AT THE 20TH ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERY SCIENCE & TECHNOLOGY
News & sentiment via Polygon.io
Explore
Browse all →
